Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
628 results in Europe PMC
PubMed plus preprints and full-text open access papers. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Non-Relapse Mortality With Bispecific Antibodies in Hematologic Malignancies: A Dual Systematic Review and Pharmacovigilance Analysis.
Irfan S, Khosla H, Nasir S, Kaur M, Varisco TJ, Ononogbu O, Singh S, Abid MB. · Hematol Oncol · 2026 · cited 1 timesmeta-analysis, systematic review
- Dual-targeting BCMA/CD19 CAR T cells with asymmetric 4-1BB/CD28-YMFM costimulation in relapsed/refractory multiple myeloma: a phase 1/2 trial with single-cell profiling of extramedullary disease.
Jiang H, Li L, Yang C, Chen K, Xie L, Ma R, Lu Y, He C, Feng F, Mei X, Wu H, Chen X, Li D, Xiao X, Cai X, Zhou T, Yuan H, Zhou Z, Ye X, Zhao J, Guan T, Ma L, Bai M, Wu G, Su L, Fu W. · J Hematol Oncol · 2026 · cited 0 timesclinical trial, phase ii, clinical trial, phase i
- Monospecific and Bispecific Chimeric Antigen Receptor (CAR) T-cell Therapy in Multiple Myeloma: A Systematic Review, Meta-analysis and Meta-regression.
Lee ARYB, Wong HJ, Lim CC, De Mel S, Ooi M, Chng WJ, Soon YY, Soekojo CY. · Transplant Cell Ther · 2026 · cited 1 timesmeta-analysis, systematic review
- Non-ICANS neurologic toxicity after BCMA CAR-T therapy: a systematic review and meta-analysis of 4630 patients with multiple myeloma.
van Besien H, Ozkan G, Easton N, Tix T, Alhomoud M, Shouval R, Rejeski K, Yamshon S. · Blood Adv · 2026 · cited 5 timesOpen accessmeta-analysis, systematic review
- BCMA-directed CAR-T cell therapy in relapsed/refractory multiple myeloma: efficacy, safety, survival, and future directions - A systematic review and meta-analysis.
Mannan MS, Musheer A, Khan MW, Abbas H, Jillani SAQ, Hafeez AS. · Curr Probl Cancer · 2026 · cited 0 timesmeta-analysis, systematic review
- Subsequent CAR-T and engineered antibody for relapsed/refractory multiple myeloma following BCMA-targeted treatment: a systematic review and meta-analysis.
Kang Y, Liu Q, Liu L, Xie W, Sun C, Mei H. · Blood Cancer J · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Efficacy and safety of BCMA- or GPRC5D-directed CD3 bispecific antibodies in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials and real-world studies.
Li J, Abulaiti A, Li D, Zhao Y, Wahafu P, Maimaitiming M, Qiu S, Zhang Y, An Y, Wang W, Shi L, Yakufu M, Shu L, Li G, Liu Z. · Front Immunol · 2026 · cited 1 timesOpen accessmeta-analysis, systematic review
- Physiological prehabilitation for patients undergoing cellular therapy in multiple myeloma and lymphoma: a systematic review.
Barredo JMS, Lim CC, Loy Y, Ooi M, Zeng Y. · Support Care Cancer · 2026 · cited 0 timessystematic review
- Infection risk associated with talquetamab in relapsed/refractory multiple myeloma: a systematic review with meta-analysis of talquetamab monotherapy and descriptive analysis of combination therapy.
Huang ZY, Wu W, Luo G, Huang H, Liu XL. · Front Immunol · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Concurrent administration of BCMA and GPRC5D CAR T cells for advanced multiple myeloma.
Mailankody S, Mitra S, Herrera K, Ziccheddu B, Cadzin B, Eren OC, Farzana T, Ullah T, Landa J, Derkach A, Chaudhari J, McAvoy DP, Hosszu K, Shah GL, Landau H, Maura F, Dogan A, Giralt S, Wang X, Sadelain M, Smith EL, Brentjens RJ, Leslie C, Usmani SZ, Perica K. · Blood · 2026 · cited 1 timesclinical trial, phase i
- Efficacy and safety of BCMA-directed CAR T-cell therapy in extramedullary relapsed or refractory multiple myeloma: a meta-analysis.
Li YL, Li MJ, Li JJ, Chen D, Li CY, Qiu L, He Y, Fan JC, Ren SH, Yao H, Fan FY. · Front Immunol · 2026 · cited 1 timesOpen accessmeta-analysis, systematic-review
- Prognostic factors for patients with relapsed or refractory multiple myeloma who are initiating a fourth or later line car T-cell or bispecific antibody therapy: a systematic literature review and meta-analysis.
Patel K, Hasegawa K, Ting J, Sidana S, Zoratti MJ, Wennersbusch D, Kanters S, Kostic A, Itani T, Hansen DK. · Expert Rev Hematol · 2026 · cited 0 timesmeta-analysis, research support, non-u.s. gov't
- CAR-HEMATOTOX score as a predictor of hematotoxicity, infection, and survival after CAR T-cell therapy in hematologic malignancies: a systematic review and meta-analysis
Wei J, Chen Z, Li M, Jiang M. · Front Oncol · cited 0 timesOpen accesssystematic-review, review
- A novel triple-knockout allogeneic BCMA CAR T-cell therapy (CT0590) for multiple myeloma: preclinical and phase 1 study.
Jin S, Liao Z, Yan S, Yan L, Yao W, Shang J, Tang F, Zhu Z, Wu D, Rajakumaraswamy N, Luo Y, Yuan D, Jiang H, Li Z, Fu C. · Blood · 2026 · cited 1 timesclinical trial, phase i
- T-cell-redirecting therapies in early relapsed multiple myeloma: a systematic review and network meta-analysis.
Merz M, Souto Filho JT, Voorhees PM, Einsele H, Schjesvold F, Cliff ERS, Mateos MV, Hungria V, Cohen YC, de Larrea CF, Beksac M, Landgren O, Usmani SZ, Costa LJ, Gagelmann N. · J Hematol Oncol · 2026 · cited 0 timesOpen accessresearch support, non-u.s. gov't, systematic review
- T-Cell Engagers Targeting <i>BCMA</i>, <i>GPRC5D</i>, or <i>FcRH5</i> in Relapsed/Refractory Multiple Myeloma: The Landscape Beyond CAR-T Cell Therapy-A Systematic Review and Network Meta-Analysis.
Shambhavi S, Joy AA, Singh H, Amonica T, Grover A, Singh T, Paul SS, Pompa T. · Int J Mol Sci · 2026 · cited 0 timesOpen accesssystematic review, review-article
- The efficacy and safety of CAR-T therapy in relapsed or refractory multiple myeloma patients: a systematic review and meta-analysis.
Zhou Y, Xie X, Feng K, Cao W, Zhang D. · Hematology · 2026 · cited 0 timesmeta-analysis, systematic review
- Hemophagocytic Lymphohistiocytosis After CAR T-Cell Therapy: A Systematic Review and Meta-Analysis.
Zhang C, Wu H, Cao T, Wu C, Yan C, Qi W, Zhang Y, Ji X, Jing H, Peng Q, Zhang W. · Am J Hematol · 2026 · cited 1 timesmeta-analysis, systematic review
- Extended follow-up of in vivo BCMA CAR-T therapy in relapsed/refractory multiple myeloma.
Xu J, Liu L, Xie W, Su L, Wang W, Li C, Liu Q, Kang Y, Zhang Y, Luo W, Huang Z, Zhang C, Sun C, Hu Y, Mei H. · Nat Med · 2026 · cited 1 timesOpen accessclinical trial, phase i
- Anti-BCMA/GPRC5D CAR T cells in patients with relapsed or refractory multiple myeloma who have extraosseous extramedullary disease.
Zhou D, Qi Y, Ma S, Sun Q, Gu W, Xia J, Zhang X, Chen W, Cheng H, Qi K, Zhu F, Xia F, Zhu L, Li H, Zhang H, Yan D, Qiu T, Zhang Y, Peng S, Sang W, Li D, Chang AH, Pan B, Yan Z. · Blood · 2026 · cited 0 timesclinical trial, phase ii
- Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma.
Frigault MJ, Dhakal B, Jakubowiak AJ, Raje N, Banerjee K, Mu CJ, Hart KC, Shachar S, Andrews LP, Cheung LS, Griffin FM, Witter AR, Hyde M, Pham C, Gandra N, Shakya T, Rajan B, Cortesio C, Haile ST, Nowyhed H, Nair-Gupta P, Mitra P, Chan RJ, Kostic A, Heery CR, Rosenblatt J, Bishop MR. · N Engl J Med · 2026 · cited 0 timesmulticenter study, clinical trial, phase i
- Arlocabtagene autoleucel: a GPRC5D-targeted CAR T-cell therapy for heavily pretreated relapsed/refractory multiple myeloma.
Bal S, Htut M, Nadeem O, Anderson LD, Gregory T, Koçoğlu MH, Rossi AC, Martin T, Egan DN, Costa LJ, Hu H, Chen J, Li S, Kelly LM, Sarkis N, Ziyad S, Jordahl KM, Kao WM, Kaeding AJ, Burgess MR, Berdeja JG. · Blood · 2026 · cited 5 timesmulticenter study, clinical trial, phase i
- Association of Ferritin Levels With Cytokine Release Syndrome in CAR T-Cell Therapy: A Systematic Review and Meta-Analysis.
Sah R, Bhattarai A, Shah S, Mehta R, Sah S, Solangi Z, Sorescu GP. · Cancer Med · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Longitudinal patient-reported outcomes and quality-of-life trajectories over 2 years in CAR-T therapy recipients.
Pizzuti VJ, Dunn A, Colborn K, Schubat M, Althaus T, Harris S, Studts JL, Schmiege SJ, Cook PF, Buckner TW, Brewer BW, Kline J, Bishop MR, Riedell PA, Major A. · Blood Neoplasia · 2026 · cited 0 timesOpen accessclinical trial
- Efficacy and safety of CD38-directed CAR-T cell therapy for multiple myeloma: a systematic review and meta-analysis.
Xu X, Dong C, Guo J, Chang X, Zhang Y, Gou S, Xue L, Li J. · Front Oncol · 2026 · cited 0 timesOpen accesssystematic review, systematic-review
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.